Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs MPLX LP (MPLX) Price & Performance

Davita IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs MPLX LP — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while MPLX LP trades at $57.6 (market cap $58.11B). The key difference: MPLX LP is far larger — about 5.1× Davita Inc's market cap, and MPLX LP pays a 7.51% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAMPLX
Market Cap
$11.29B$58.11B
Volume
582,204687,483
Sector
HealthEnergy
52-Week High
$240.96$60.51
52-Week Low
$103.87$47.80
Typical Hold Time
113 Days—
Enterprise Value
$24.01B$83.22B
Dividend Yield
—7.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.

The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.

MPLX LP

MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations in Q1 and Q2 2026. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and a resilient midstream business model that limits commodity price exposure.

The outlook is cautiously optimistic given MPLX's fee-based revenue structure and 67.86% buy rating from analysts. Key risks include energy market volatility and potential diesel export restrictions, but the company's distribution coverage ratio of 1.3x supports dividend sustainability. Upside potential exists if Q3 earnings meet or exceed the $1.15 EPS estimate due November 3, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
MPLX

No sentiment data available yet.

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

Read more on MPLX →